S. Popov: The result was that prototypes of the relevant agents were developed, which were highly appealing to the client. The client was... of course the Ministry of Defence was the client. So, prototypes were developed according to the idea that if we now make a virus vaccine, a virus which is a vaccine formula, if we go from the vaccine formula to the real virus then the mortality from smallpox will be one hundred per cent. Thirty per cent will die following infection by the formula... [the rest] will recover and then the people who are left who have recovered will die in two weeks. So that was one of the autoimmune prototypes, or what is it called? An autoimmune response. Another prototype was, let's say, "frantsisella tularemia." If such a tularemia had been designed, and it had produced narcotic peptides, then mortality would have been much more elevated, treatment with antibiotics would have been utterly useless, and the objective of designing a formula that was resistant to antibiotics would have been met.